21 22 channel states, thus explaining their lesser efficacy, yet also populate agonist-bound open and 32 desensitized states. Measurements within the neurotransmitter binding pocket, as a function of 33 bound agonist, provide a metric to correlate the extent of agonist-induced conformational changes 34 to open channel probability across the Cys-loop receptor family. 35 36 to change the conformation to a short-lived pre-open intermediate (flipped/primed), rather than 62
Summary 23
The glycine receptor is a pentameric, neurotransmitter-activated ion channel that transitions Drugs that activate receptors (agonists) can differ in their effectiveness and produce 38 different maximum responses on the same receptors 1 . This property is called efficacy by 39 pharmacologists, and agonists with low efficacy are known as "partial agonists", a term coined by 40
Stephenson in 1956 2 . Early work by del Castillo and Katz 3 on the muscle nicotinic acetylcholine 41
ACh receptor (nAChR), a member of the pentameric ligand-gated channel superfamily (pLGIC), 42
led to the hypothesis that efficacy is determined by the agonist's ability to keep the channel open 43 after it has bound. In LGICs, agonist efficacy is reflected in the maximum open probability seen 44 in single-channel recordings when the channel is fully occupied by the agonist. Neurotransmitters 45 are often full agonists 4,5 , as exemplified by ACh on the muscle nAChR and glycine on the glycine 46 receptor (GlyR), but partial agonists are of interest in therapeutics and include varenicline 6 , a 47 partial agonist of neuronal nAChR, used as an aid to smoking cessation. Moreover, in the auditory 48 system, GABA, a partial agonist of GlyRs, is co-released with glycine and both agonists act on 49 the GlyR to sculpt receptor decay kinetics and the time course of postsynaptic responses 7 . 50 pLGICs include important therapeutic targets, such as neuronal and muscle nAChR, 51 GABA receptors and 5-HT3 receptors (5-HT3R) 8 . Among pLGICs, GlyRs are an vehicle through 52 which to investigate the mechanism of agonist efficacy because they can be studied by both 53 single-molecule electrophysiological measurements of efficacy and high resolution structural 54 studies. Recent electrophysiological studies of GlyRs showed that channel activation is not a 55 simple isomerization from resting to open states, but rather involves a more complex landscape 56 of one or more pre-open intermediates 4, 9, 10 . The presence of multiple agonist-bound closed states 57 is a general feature of the pLGIC superfamily and there is substantial evidence that the closed 58 intermediate states stabilized by agonist binding have increased affinity for the agonist [11] [12] [13] [14] . Fitting 59 models that include activation intermediates to GlyR, nAChR and 5-HT3R single channel data 60 have led to the proposal that the limited efficacy of partial agonists is due to their reduced ability 61 states while the channel is not desensitized, especially for GABA, suggesting the presence of a 138 substantial population of partial agonist-bound shut states ( Fig. 2a) . Indeed, the maximum PO for 139 taurine and GABA is 66% and 39%, respectively, substantially lower than that of glycine (97%; 140 Fig. 1a ). The partial agonists are also less potent, with effective concentrations (EC50) for taurine 141 and GABA of 1050 ± 80 µM and 28.4 ± 0.9 mM, respectively (cf. glycine: 190 ± 20 µM; Fig. 2c ). 142
In the subsequent structural studies, we applied 20 mM taurine and 40 mM GABA to the receptor 143 isolated in SMA or reconstituted into nanodiscs. 144
Three-dimensional classification of the SMA and nanodisc cryo-EM data sets, for each 145 partial agonist, reveals 4 and 2 distinct classes, respectively, with overall resolutions of 2.8 to 3.3 146 Å and local resolutions as high as 2.5 Å in the extracellular domain (ECD) (Extended Data Fig. 8  147 and 9, Supplementary Tables 1-3 and 5, Supplementary Fig. 2, 4 , 5). In the SMA data sets, three 148 of the four taurine-or GABA-bound structures are overall similar to the glycine-bound structures 149
and correspond to open, desensitized, and super-open states ( Fig. 2d-k) . By contrast, in the 150 nanodisc data sets, one of the two structures is reminiscent of the glycine-bound desensitized 151 state and we did not observe the open and super-open states as in the SMA data sets, supporting 152 the notion that native lipids extracted by SMA best enable the receptor to occupy physiologically 153 relevant states (Extended Data Fig. 1d, e) . 154
We discovered a previously unseen, partial agonist-bound conformation of the receptor, 155 observed with taurine and GABA, and in both the SMA preparation and the receptor in nanodiscs. 156
In these reconstructions, there is clear density for the partial agonists in the orthosteric binding 157 pocket (Supplementary figure 6) and the M2 helices are oriented approximately perpendicular to 158 the membrane. In these partial agonist-bound structures, the pore is closed, as the side chains of 159 9'L point to the center of the channel, creating a constriction less than 3 Å in diameter and thus 160 rendering the channel impermeable to Cl - (Fig. 2f , i, j, k, Extended Data Fig. 1d-f ). At the -2'P site, The closed state observed in the partial agonist-bound cryo-EM datasets provides the first 164 structural visualization of the long-lived shut states in single-channel recordings, and is consistent 165 with these shut states being most highly populated in the presence of partial agonists ( Fig. 2a) . 166
By contrast, the glycine-bound closed conformation of the receptor is short-lived, as the receptor 167 rapidly and nearly completely transitions to the brief intermediate "flipped" state 12 , thus precluding 168 its capture by single-particle cryo-EM. Taurine or GABA's less potent ability to 'flip' GlyR, as well 169
as their propensity to promote the receptor's return from the flipped state to the closed state, 170 allows us to capture agonist-bound closed states via cryo-EM. We suggest that the cryo-EM 171 partial agonist closed states, bound with either GABA or taurine, most likely represent agonist-172 bound, unflipped states. In each cryo-EM dataset, the fraction of particles in each state is roughly 173 related to the likelihood of the receptor occupying that conformation. The particle fractions of the 174 open or desensitized states decrease for taurine as compared to glycine, and decrease further 175 for GABA. Conversely, the fraction of particles in the closed state is highest for the GABA dataset, 176 lower for the taurine dataset, and absent in the glycine dataset ( Fig. 2b ). These findings are 177 consistent with single-channel recordings, showing GABA having the lowest efficacy for activating 178 GlyR, followed by taurine, with glycine having the highest efficacy. 179
Neurotransmitter binding site 180
In all complexes, the densities for glycine, taurine and GABA are distinctive and well 181 defined, enabling accurate definition of the positions and poses of the agonists (Fig. 3a- 
c, 182
Extended Data Figs. 7, 8 and 9). In the glycine complex, the agonist's amino group forms 183 hydrogen bonds with the backbone carbonyl oxygen of Phe175 (loop B) and a cation-π interaction 184 with Phe223 (loop C), while the carboxyl group interacts with Thr220 (loop C), Arg81 (β2) and 185 Ser145 (β6) ( Fig. 3d ), consistent with the GlyR-α3 crystal structure 22 . While the orientation of 186 taurine and GABA is similar to that of glycine, the interactions between the amino groups of the 187 agonists and receptor residues are different ( Fig. 3e-f ). In the taurine complex, an additional 188 hydrogen bond is formed between the amino group and the backbone carbonyl oxygen of Ser174 189 whereas no cation-π interactions with Phe223 were identified ( Fig. 3e ). In the GABA complex, the 190 amino group forms hydrogen bonds with the backbone carbonyl oxygen of Ser174 and Glu173 191 (loop B) ( Fig. 3f ). As in the glycine complex, the sulfate group of taurine and the carboxylate group 192 of GABA participate in hydrogen bonds with Thr220, Arg81 and Ser145. 193 To identify the changes in the binding pocket upon agonist binding, we solved the structure 194 of a functional receptor variant with a truncated M3/M4 loop in the apo/resting state (apo-GlyREM; 195 Supplementary Table 4 ). Because the M3/M4 loop is far from the agonist 196 binding site, and because the apo receptor is in a closed/resting state conformation, the loop 197 deletion does not substantially affect receptor conformation in the apo state. Indeed, the apo-198
GlyREM structure has a pore constriction at 9'Leu, consistent with the apo-GluCl 31 and 199 taurine/GABA-bound closed sate (Extended Data Fig. 1f ). Upon comparison of the apo/resting 200 state conformation of the agonist binding pocket with the open state/agonist-bound complexes, 201
the binding pocket has a profound 'contraction' that largely involves loop C transitioning from an 202 "uncapped" to "capped" configuration and loop B moving towards to the agonist (Fig. 3i) , 203 reminiscent of conformational changes in the acetylcholine receptors 14, 32, 33 . 204
The extent of binding pocket contraction, however, is different between full and partial 205 agonists, with the volume of the agonist binding pocket smallest in the glycine-bound structure. 206
Thr220 in loop C, Phe175 in loop B, Arg81 in β2, and Ser145 in β6 all coordinate taurine and 207 GABA similarly, yet slightly different than their coordination of glycine. In the glycine complex, the 208 Cα atoms of Thr220 in loop C and Phe175 in loop B 'contract' toward the agonist by 0.5 Å and 209 0.6 Å, respectively, compared with the taurine-bound pocket (Fig. 3g, h ). We propose that these 210 conformational changes are coupled to agonist-induced activation 29 , consistent with the notion 211 that the agonist has an increased stabilization of the activated configuration 34 . Thus, in the full 212 agonist open state, loops B and C move closer to the ligand in comparison to partial agonists, 213 resulting in a smaller binding pocket and a more efficient activation of the receptor (Fig. 3h ). Our 214 structural data, together with agonist-dependent measurements on the AChR, 5HT-3 and GABA 215 receptor, show that full and partial agonist complexes of the open state of a Cys-loop receptor, 216 within the confines of the agonist-binding site, are not identical and that full agonists yield a more 217 'compact' binding site in comparison to partial agonists ( Supplementary Table 6 ). 218
GABA acts on YGF mutant with a high Po 219
To test if contraction of the agonist binding pocket by partial agonists is correlated to 220 agonist efficacy, we investigated the F175Y/Y177F variant (YGF) 19 , a double mutant that involves 221 only a single oxygen atom swap from one residue to another. Remarkably, GABA is an almost 222 full agonist on the YGF mutant, with a Po of ~96% (Fig. 4b ). In the mutant, the potency of GABA 223 in activating the channel (EC50) and in displacing [H 3 ]-strychnine (Ki) also increases by 15-and 224 8-fold, respectively. Importantly, glycine remains a full agonist, with a Po of nearly 1.0, and the 5-225 fold decrease in its EC50 suggests glycine efficacy is also increased ( Fig. 4a ). To explore the 226 structural basis for the increase in GABA potency, we solved the cryo-EM structure of the YGF 227 Supplementary Table 4 ). Importantly, we did not observe any 3D classes associated with the 230 closed state of the receptor, corroborating the electrophysiological data showing that GABA acts 231 as a nearly full agonist on the YGF mutant. 232
The increased binding affinity of GABA to the YGF mutant arises from additional 233 interactions involving the carboxylate group of GABA, including a hydrogen bond with the hydroxyl 234 oxygen of Tyr175 ( Fig. 4d ). Superposition of the binding pockets of the WT and YGF mutant 235 highlights other differences between interactions by receptor side chains. The mutation of Tyr177 236
to Phe disrupts the hydrogen bond formed with Trp110 through the hydroxyl oxygen of Tyr177, 237
whereas the mutation of Phe175 to Tyr yields an additional hydrogen bond with Ser145 ( Fig. 4e ). 238
These new receptor interactions enable loop B, on which Tyr175 and Phe177 reside, to move 239 closer to the (-) subunit, reducing the binding pocket volume to a value similar to that of the WT 240 glycine open complex ( Fig. 4f, g) . Thus, binding pocket volume is a key determinant of agonist efficacy, and contraction in the binding pocket facilitates transition of the receptor from the resting 242 state to the flipped and, ultimately, the open state. 243
To understand why GABA is almost a full agonist at the GABA receptor (GABAR) but a 244 partial agonist for GlyR, we also superimposed the binding pocket of GlyR with the canonical 245 GABA binding site of the GABAR 35, 36 . Remarkably, most of the residues coordinating GABA in 246 the two receptors are identical, with the exception of Tyr97, Tyr157, and Tyr205 in GABAR, which 247 are Phe115, Phe175 and Phe223 in GlyR, respectively (Extended Data Fig. 5a, b ). Moreover, the 248 binding pocket of the GlyR open state has a smaller volume than GABA-bound GABAR (Extended 249 Data Fig. 5c ), implying that the opening of GABAR requires a smaller contraction of the binding 250 pocket to fully transition the receptor to the open state. To explore if the simple substitution of the 251 three tyrosine residues of GABAR with the phenylalanine residues of GlyR enables GABA to act 252 as a full agonist on the GlyR, we prepared the YYY mutant (F115Y/F175Y/F223Y) and found that 253 GABA remained a weak partial agonist, with a similar Po in the YYY mutant as in the WT receptor 254 (Extended Data Fig. 5d ). Thus, the tuning of agonist efficacy requires precise changes in the 255 pocket volume and in agonist-receptor interactions that go beyond which residues interact directly 256 apo-GlyREM and apo 5-HT3AR to investigate the conformational changes in the ECD and ECD-294 TMD interfaces (Extended Data Fig. 6a-e ). In the binding pockets, loop C in the tau-closed state 295 is in a "capped" configuration as compared to the other two structures, likely due to the binding of 296 agonist, further supporting our view that the tau-closed is distinct from the resting state (Extended 297 Data Fig. 6a-b ). While the ligand binding pocket shows substantial conformational differences 298 between the apo-GlyREM and tau-closed structures, the ECD-TMD interfaces of the two structures 299 are remarkably similar, with identical conformations for M2-M3, β1-β2, β8-β9 and Cys loops 300 (Extended Data Fig. 6d ), suggesting that local movements of loop C alone cannot induce 301 substantial conformational changes that affect the receptor ECD-TMD interfaces as well as the 302
TMDs. Much like the ligand binding pocket, the 5-HT3AR ECD-TMD interface shows profound 303 differences compared with the tau-closed state (Extended Data Fig. 6c , e). 304
Conformational changes of the ion channel pore 305
To visualize the conformational changes at the TMD coupled with the movements of ECD 306 and ECD-TMD interfaces, we compared the TMDs from tau-closed, tau-open and tau-307 desensitized states. In the transition from the closed to the open states, the whole TMD of each 308 subunit undergoes a counterclockwise outward rotation of ~8.6 ° relative to the pore axis, viewed 309 from the extracellular side, expanding the pore size by moving the Cα atoms of 9'L and -2'P by 2 310 Å and 1 Å, respectively, opening the ion channel pore and allowing for the passage of Cl - (Fig. 5a , 311 i, j and Extended Data Fig. 6f ). Among the M1-M4 helices, the M2 helices have a more 312 pronounced movement, with a rotation of ~13°. During the transition from the open to the 313 desensitized state, the major conformational changes are in the TMD, with each subunit 314 undergoing a clockwise rotation by ~2° (Extended Data Fig. 6g ). As a consequence, although the 315 extracellular upper half of the pore has a small movement at 9'L, the intracellular lower half of the 316 pore is occluded at -2'P, moving by ~1.4 Å, in agreement with observations in the homomeric-317 GABAA receptor and the α4β2 nicotinic receptor in the desensitized state 46-48 ( Fig. 5a , h, j). In this 318 process, the M2 helix exhibits a larger motion, with an inward rotation of ~3°. Notably, the M1-M2 319 loop undergoes a relatively large displacement during desensitization, in agreement with studies 320
showing that mutation of the M1-M2 loop can strongly affect entry into desensitization 49, 50 . 321
Partial agonist gating mechanism 322
Previously unseen partial agonist-bound closed states, poised between the resting and 323 flipped state, have now been captured, in accord with the observed long-lived shut state in the 324 single-channel recordings ( Fig. 2a ). Binding of the partial agonist induces a contraction in the 325 binding pocket, yet to a lesser extent than the full agonist ( Fig. 6a-c) . These ECD changes 326 promote the receptor transition from the closed to open state, in which the TMD undergoes an 327 outward rotation and expands the channel pore at the -2'P and 9'L positions ( Fig. 6c ). Sustained 328 binding of agonist promotes a further transition into the desensitized state, involving an inward 329 rotation of the TMD and occlusion of the pore at -2'P ( Fig. 6d ). Methods 649
Protein purification and nanodisc reconstitution 650
The cDNA encoding the full-length zebrafish α1 glycine receptor (GlyR, NP_571477), with 651 the following modifications, was cloned into the pFastBac1 vector for baculovirus expression in 652 the Sf9 insect cells 20 . A thrombin cleavage sequence (Leu-Val-Pro-Arg-Ser) was introduced after 653 the carboxy terminus of GlyR and before an octa-histidine tag. The truncation of GlyR (GlyREM), 654 in which the long M3-M4 loop replaced by an Ala-Gly-Thr tripeptide, were engineered based on 655 the wild-type (WT) background. The YGF mutant, where residues Phe175 and Tyr177 were 656 swapped, were generated using site-directed mutagenesis. WT receptor and YGF mutant were 657 purified in the same procedures. Following transduction of insect cells with baculovirus and cell (SEC) Superose 6 10/300 GL column for further purification using a TBS buffer supplemented 669 with 1 mM C12M and 0.25 mM CHS. The peak fractions were collected and concentrated to ~16 670 µM receptor concentration for reconstitution into lipid nanodiscs or used for cryo-EM studies. 671
To remove unbound and bound glycine to enable determination of the apo-GlyREM 672 structure, all the buffers were prepared using HPLC water (Sigma) and extensive dialysis was 673 carried out as follows. The pelleted membrane with a volume of 30 mls was homogenized and 674 incubated with 100 nM strychnine. The strychnine saturated membranes were transferred to an 675 8-10 kDa molecular weight cut off cellulose ester dialysis tubing (Spectra/PorBiotech) and 676 dialyzed in 200-fold volume of glycine-free buffer containing 150 mM NaCl, 20 mM Tris 8.0 (TBS 677 buffer in HPLC water) in the presence of 1 mM PMSF, 0.8 µM aprotinin, 2 µg/ml leupeptin, and 2 678 mM pepstatin A. Buffer exchange was carried out twice a day over the course of five days at 4°C, 679 resulting in 10 changes. 680
To incorporate the receptor in lipid nanodiscs 51 , brain total lipid extract (BTL, Avanti) 681 dissolved in chloroform was dried down using a rotary evaporator and resuspended in a TBS 682 buffer supplemented with 20 mM C12M and 2.5 mM CHS to a final lipid concentration of 10 mM. 683
Because we estimate that the diameter of the GlyR transmembrane domain is ~80 Å, we used 684 the MSP1E3D1 scaffold protein which, in turn, yields nanodiscs with an outer diameter of ~12 nm. 685 MSP1E3D1 was purified through metal chelate affinity column (Ni-NTA) and extensive dialysis 686 against TBS buffer 52 . GlyR was mixed with MSP1E3D1 and BTL in a final ratio of 1: 7.5: 200 687 (molar ratios) and incubated for 40 min by gentle agitation at 4 °C. Detergent was removed by 688 adding Bio-Beads (SM2, Bio-Rad) to a final concentration of 150 mg/ml. After incubation for 2 689 hours, the Bio-Beads were replaced with fresh beads. The mixture was incubated overnight at 690 4 °C. After separation from Bio-beads, the protein was loaded onto a Superose 6 10/300 GL 691 column equilibrated with TBS buffer. Peak fractions corresponding to reconstituted GlyR were 692 collected for cryo-EM analysis and scintillation-proximity assay (SPA) 53 . 693
Protein purification via styrene maleic acid (SMA) copolymer solubilization 694
The SMA copolymer XIRAN 30010 (~2.3:1 molar ratio of stryrene: maleic acid) was 695 purchased from Polyscope as an aqueous solution of 20% (w/v) SMA. The purification procedures 696 in the context of the SMA copolymer are similar to those previously described except for the 697 following differences. Following collection of the membrane fraction by centrifugation, the 698 membranes were resuspended in TBS buffer and XIRAN 30010 was added to a final 699 concentration of 0.5% with slow stirring at 4 °C for 1 h. After ultracentrifugation for 1 hr at 40,000 700 RPM (Ti45 rotor), the supernatant was collected and incubated with NTA metal ion affinity resin 701
for 5-6 hours. The remaining purification steps were carried out as described above with the 702 caveat that no additional SMA or detergents were added throughout the remaining purification 703 steps. Following SEC chromatography, the WT/YGF mutant-SMA complex was concentrated to 704 2 mg/ml for cryo-EM analysis. 705
Determination of glycine contamination 706
Potential glycine contamination in 50 mg/ml stocks of taurine or GABA was analyzed using 707 liquid chromatography tandem mass spectrometry (LC-MS/MS) with electrospray ionization in 708 positive mode. MRM (multiple reaction monitoring) transitions monitored specific product ion 709 fragment from glycine. The reported major fragments were 75.9/48 and 75.9/30.2. Standards 710 spiked with 0.1 µg/ml to 50 µg/ml glycine in presence of a constant concentration of 50 mg/ml of 711 GABA or taurine were prepared as control to test assay sensitivity. The glycine contents in the 50 712 mg/ml stocks of taurine or GABA were below the lower limit of detection, 0.1 µg/ml. These 713 experiments allowed us to estimate that the extent of glycine contamination was less than 1.33 714 µM of glycine in 0.4 M of taurine or 0.49 M of GABA. 715
Ligand binding assay 716
Competition ligand binding experiments were carried out using the SPA 53 and a solution 717 containing 40 nM WT receptor or YGF mutant reconstituted into the SMA, 1 mg/ml Cu-Ysi beads, 
Cryo-EM sample preparation and data acquisition 726
To prepare the GlyR complexes with different agonists, the WT receptor complexes in 727 nanodisc or SMA were mixed with 10 mM glycine, 20 mM taurine or 40 mM γ-aminobutyric acid 728 (GABA) immediately before the samples were placed onto the grids. Apo-GlyREM sample was 729 placed onto the grid directly. For preparing the YGF mutant complexes with 40 mM GABA, it 730 followed the same procedures as WT receptor. We estimate that the time elapsed between mixing 731 of receptor with agonist and plunge freezing of the grids was around 10 s. In addition, the extent 732 of glycine contamination in the taurine and GABA chemicals was estimated as less than 1.33 µM 733 in 0.4 M of taurine or 0.49 M of GABA, as described below. To minimize preferred orientation, the 734 nanodisc-reconstituted receptor solutions were supplemented with 60 µM perfluoro octyl 735 maltoside (FOM) prior to grid preparation. A 2.5 µL sample of receptor was applied to glow-736 discharged Quantifoil R1.2/1.3 or 2/2 200 mesh gold holey carbon grids which were then blotted 737 for 2.5 s under 100% humidity at 12 °C. The grids were then flash-frozen in liquid ethane, 738 maintained at melting temperature, using a FEI Mark IV cryo-plunge instrument. For the wild type receptor complexes in SMA, all the datasets were collected on a 300 kV 746 FEI Titan Krios microscope equipped with an energy filter (Gatan Image Filter) set to 20 eV. 747
Images were acquired on a K2 Summit direct-detector positioned after the energy filter using 748 super-resolution mode at 165,000 magnification and a pixel size of 0.412 Å. Images were 749 collected using 'multishot' methods driven by SerialEM 54 with seven shots per hole utilizing 2/2 750 200 mesh grids and a defocus ranging from -1.0 µm to -2.0 µm. Each micrograph was recorded 751 over 40 frames with a total dose of 42 e − /Å 2 . For the YGF mutant in complex with GABA, the 752 dataset was collected on the same Titan Krios microscope as the wild type, but images were 753 acquired on a K3 BioQuantum direct-detector using super-resolution mode at 135, 000 754 magnification with a pixel size of 0.65 Å. Each micrograph was recorded over 60 frames at a dose 755 rate of ~18.76 e − /pixel/s and a total exposure time of 1.5 s, resulting in total dose rate of 62 e − /Å 2 . 756
The data for apo-GlyREM was collected on a 300 kV FEI Titan Krios at the cryo-EM facility 757 at the Janelia Research Campus. This microscope is equipped with a CETCOR Image Corrector 758 for spherical aberration correction and an energy filter. A 20eV energy slit centered on the zero-759 loss peak, and a Cs of 0.01 mm were used during data collection. All micrographs were recorded 760 on a Gatan K2 Summit direct electron detector operated in super-resolution counting mode with 761 a pixel size of 1.04 Å. The dose-fractionated images were recorded using the automated 762 acquisition program SerialEM 54 . Each micrograph was recorded over 30 frames with a total 763 exposure time of 6 s, resulting in total dose rate of 54 e − /Å 2 . 764
Image processing 765
Super-resolution image stacks were 2×2 binned in the Fourier space and motion corrected 766
by Motion Cor2 55 . The contrast transfer function (CTF) parameters were estimated by Gctf 56 and 767 particles were picked by DoG-picker 57 for all the datasets except for indicated. 768
We first analyzed the taurine-bound GlyR-nanodisc complex data, culling through the total 769 micrographs and retaining 1,264 micrographs that had Thon rings extending to at least 4 Å. 770
Approximately 669,253 particles were picked from these micrographs and subjected to 2D 771 classification in Relion 2.1 58 . After several rounds of classification, 2D classes with clearly defined 772 features of the glycine receptor contained 244,309 particles. This particle stack was then 773 employed for subsequent analysis. An initial model generated from cryoSPARC 59 was then used 774 for 3D classification and refinement. A soft mask with extending binary map of 4 pixels and a soft-775 edge of 6 pixels and C5 symmetry were applied during all the following steps of classification and 776 refinement. Two of the 3D classes (class1 and class 3) showed reasonable secondary structure 777 features and were subjected to 3D refinement, yielding two different maps belonging to what we 778 define as the desensitized and closed states, respectively. To reduce heterogeneity among these 779 two classes and improve the density in the transmembrane regions, class 1 and class 3 were re-780 classified into three classes. For class1, this resulted in an additional class 1a (45,300 particles) 781 and class 1b (79,557 particles) with the same transmembrane helix orientation and density. We 782 therefore combined these classes and carried out 3D refinement, which yielded a map that we 783 identify as the taurine-bound desensitized state. For class 3, the resulting class 3b contained only 784 15,292 particles, albeit with a better density in the transmembrane region. This class was selected 785 for the 3D refinement, yielding a map that we identify as the taurine-bound closed state (Extended 786 Data Fig. 8 and Supplementary Fig. 1) . 787
A similar procedure was used to process data associated with the GABA-bound receptor 788 in nanodiscs. Briefly, 493,873 particles were auto-picked from 1,109 micrographs and were 789 subjected to 2D and then 3D classification. Two different classes containing 39,926 and 38,383 790 particles were selected for 3D reconstruction and 3D auto-refinement respectively, giving rise to 791 one map that we identify as the GABA-bound desensitized state and a second map that we 792 believe represents the GABA-bound receptor in a closed state (Extended Data Fig. 9 ). 793
The single particle cryo-EM data for the glycine-bound receptor in nanodiscs was 794 processed using similar procedures. To do this, 472,910 particles were auto-picked from 1,231 795 micrographs and subjected to 2D and 3D classification. Notably, the 3D classes shared the same 796 overall shape and transmembrane helix orientation, suggesting the preponderance of one 797 conformational state in this glycine-bound data set. Three classes (80,121 particles) with good 798 secondary structure features were combined and used for 3D auto-refinement, yielding a map 799 that we define as the glycine-bound desensitized state (Extended Data Fig. 7) . 800
For the glycine bound receptor in the SMA, a total of 5309 micrographs were retained 801 followed the same criteria as above. A total of 1,578k particles were picked by DoG-picker and 802
Relion-3.0 60 was used for 2D classification, 3D auto-refinement and 3D classification. 4× binned 803 particles were extracted followed by one round of 2D classification by limiting the resolution to 8Å. 804
After this round of 2D classification, only these classes with clear receptor features and clean 805 background were selected. 804k 'good' particles were selected and 2× binned particles were re-806 extracted followed by one round of 3D refinement using a filtered map and an initial model derived 807 from the previous structure determination of GlyR (PDB code: 3jaf). Additional 3D classification 808 was performed using the refined 2× binned particles by applying C1 or C5 symmetry with 809 alignment. The 3D classifications with C1 symmetry yielded similar classes as with C5 symmetry, 810 albeit with slight weaker TM density, thus justifying the imposition of C5 symmetry. The 172k 811 particles belong to the dominant class6 were selected and unbinned particles were re-extracted 812 and re-centered followed by another round of 3D refinement. Using the refined unbinned particle 813 stack, 6 classes were generated during the 3D classification without alignment. Based on the 814 differences of the M2 helices in these classes, 84978, 155456 and 39586 particles belong to the 815 putative open state (class 6a), the desensitized state (class 6b), and the 'super-open' state (class 816 6c) were re-extracted for 3D auto-refinement (Extended Data Fig. 7) . 817
Similar procedures were performed for the taurine-bound SMA data set. Here, 5004 818 movies yielded 1124k particles that were automatically selected using template based particle 819 picking in Relion-3.0 60 . 4× binned particles were extracted followed by one round of 2D 820 classification. 543k 'good' particles were retained and unbinned particles were extracted. After 3D 821 classification, four different classes containing 17873, 17271, 122322 and 74365 particles were 822 isolated and were used in 3D auto-refinement, giving rise to the density maps of the taurine-bound 823
closed, taurine-bound desensitized, taurine-bound open and taurine-bound super-open states, 824
respectively (Extended Data Fig. 8 and Supplementary Fig. 2) . For the GABA-bound complex in 825 SMA, a total of 2062 k particles were extracted from 5,200 micrographs and were subjected to 826 2D and 3D classification that the classes without obvious receptor features were dumped. Four 827 different classes containing 121470, 150199, 20845 and 31667 particles were selected for 3D 828 reconstruction and 3D auto-refinement respectively, giving rise to four maps that we identify as 829 super-open, open, desensitized and closed states, respectively (Extended Data Fig. 9 ). For the 830 GABA-bound YGF mutant complex in SMA, a total of 1800k particles extracted from 9,300 831 micrographs were subjected to the following 2D and 3D classification. The resulted 407k particles 832 produced two classes containing 32386, 27496 and 42097 particles that we identified as open, 833 desensitized and super-open states, respectively (Extended Data Fig. 10) . 834
For the apo-GlyREM in the micelle, approximately 1000 particles were manually picked for 835 an initial reference-free 2D classification. Seven to eight representative 2D class averages were 836 selected as templates for automated particle picking using Relion 2.1 58 or GAUTOMATCH 837 loop receptors were then selected. Particles belonging to the chosen classes, with a number of 843 115, 864, were used for 3D auto-refinement ( Supplementary Fig. 3) . 844
To improve the density in the transmembrane region, all the refined maps from Relion 845 2.1/3.0 58,60 were further refined using auto refinement in cisTEM 61 , yielding well-defined maps. 846
The final reconstructions for the receptor in the nanodiscs were subjected to post-processing in 847 the Relion 2.1, and for the reconstructions of the receptor in SMA, the maps were sharpened by 848
Localscale 62 . Local resolution was determined by Relion 3.0 60 . The reported resolutions in the 849
Extended Table 1 and Extended Table 2 were estimated by gold standard FSC 0.143 criteria 63 . 850
Model building 851
The model building commenced with rigid body fitting of an initial model derived from the 852 prior GlyR structures to each density map followed by real space refinement in Coot 64 and by 853 using Phenix 65 . To build all of the desensitized protein structures, the taurine-bound desensitized 854 state structure in nanodisc (taurine_desensitized_nanodisc) was first built and then was used as 855 the initial structure for the other desensitized state complexes. We began by fitting the 856 glycine/ivermectin-bound protein structure (PDB code: 3jaf), excluding the ligands, into the 857 taurine-bound desensitized state map using UCSF Chimera 66 . The resulting structure was 858 manually adjusted in Coot, guided by well resolved side chain densities. Amino acid residues 859 missing from the previously determined glycine/ivermectin protein structure were added, including 860 H327 at the end of the M3 helix and E390, M391 and R392at the beginning of the M4 helix. 861
Prominent tube-shaped electron density surrounding the receptor transmembrane domain (TMD) 862 likely arises from ordered lipid molecules and thus alkane chains with appropriate lengths were 863 placed in the density features. The structure was further refined using Phenix in the context of 864 restraints for stereochemistry of the alkane chains and carbohydrate groups. After Phenix 865 refinement, the map to model cross correlation (cc) value between the final model and the map 866 was 0.83. To build the other desensitized state structures, the above determined structure 867 taurine_desensitized_nanodisc was fitted to the density maps using UCSF chimera. After rigid-868 body fitting of the taurine_desensitized_nanodisc model, taurine was replaced with the 869 appropriate ligands, alkane chains were either replaced with appropriate lengths in these 870 nanodisc structures or removed in the SMA structures, and the models were then real-space 871 refined in Coot and Phenix. Specifically, two amino acids -V388 and E399 -were added at the 872 beginning of the M4 helix in these protein structures of the desensitized state in SMA. (taurine_closed_nanodisc), we found that the previously determined strychnine-bound structure 891 (PDB code: 3jad) fit the map well and thus it was used as an initial model. The structure was fit to 892 the taurine-bound closed state map using UCSF Chimera. Chain A of the superimposed model 893 was further optimized by real space refinement using Coot, including fitting of a taurine molecule 894 to the density in the neurotransmitter binding pocket, adding Q326 and H327 at the end of the M3 895 and E390, M391 and R392 at the beginning of M4 helices, manually building the M2-M3 loop and 896 adding lipid-derived alkane chains surrounding TMD. The model generated in Coot was further 897 refined against the density map by Phenix. The cc between the taurine_closed_nanodisc and its 898 corresponding map was 0.81. To build the other state protein structures either in nanodisc or 899 SMA, the Phenix refined taurine_closed_nanodisc coordinates were used as the initial structure. 900
Coot was used to change the ligands and removed the alkane chains in SMA structures or 901 replaced with appropriate lengths in nanodisc structures based on the density features, followed 902 by Phenix refinement. All of the final models have good stereochemistry as evaluated by 903 molprobity 67 ( Supplementary Tables 1-4 ). All the figures were prepared by Pymol (Schrödinger, 904 LLC) and UCSF chimera 68 . Pore radii were calculated using program Hole 69 . 905
Molecular dynamics simulations 906
Two types of molecular dynamics (MD) simulations were conducted to investigate the permeation 907
properties of the experimentally derived structural models, respectively. The membrane 908 composition used in the simulations corresponded to the HEK cytoplasmic membrane (24% 909 POPS, 7% POPI, 3% POPG, 11% sphingomyelin, 16% POPE, 36% POPC, and 3% cholesterol). 910
Only the transmembrane domain (residue 244-436) was simulated for the glycine-bound 911 desensitized, open, and super-open state structural models embedded in lipid bilayers for 500 ns 912 each. To verify that these channel structures can be blocked by toxins as observed experimentally, 913 an additional set of simulations were performed in the presence of a channel blocker, picrotoxinin, 914 for each of the three states using the same protocol for 500 ns. 915 CHARMM-GUI 70 was used to construct the initial lipid bilayers with a cross-sectional of 180 × 180 916 Å 2 . VMD 71 was used for other steps of system preparation. The proteins were embedded into the 917 membranes as previously described 25 . A picrotoxinin was added to each protein near the -2'P 918 gate when preparing for ion channel blocking studies. Then, all systems were neutralized and 919 solvated in a 150 mM NaCl. Each system had a final dimension of 180 × 180 × 150 Å 3 . NAMD 920 2.12 72 was used to perform all of the simulations. 921
Each simulation started with 3,000 steps of energy minimization with phospholipid phosphorus 922 atoms, hydroxyl oxygen of cholesterol, and protein side chain heavy atoms restrained (k = 1 923 kcal.mol -1 .Å -2 ), along with additional restraints on the protein backbone atoms (k = 50 kcal.mol -924 1 .Å -2 ), followed by a 0.5 ns equilibration of lipid tails. To relax the membrane lipids around the 925 protein, a 20-ns simulation was performed where only protein backbone and ligand heavy atoms 926 were restrained (k = 50 kcal.mol -1 .Å -2 ). Then, the simulations continued with only protein backbone 927 atoms restrained (k = 1 kcal.mol -1 .Å -2 ), and with a transmembrane voltage of -100 mV applied 928
throughout. 929
To maintain the constant pressure of 1 atm in our NPT simulations, the Nosé-Hoover piston 73,74 930 with an oscillation period of 200 fs and a damping time scale of 100 fs was used. A constant 931 temperature of 310 K was maintained by coupling all of the non-hydrogen atoms to a Langevin 932 thermostat with a damping coefficient of 1.0 ps -1 . The SETTLE algorithm 75 was used to keep the 933 covalent bonds involving hydrogens rigid. The TIP3P 76 model was used for the water molecules. 934
We chose 2 fs time steps for the simulations. To calculate the long-range electrostatic interactions, 935 the PME method 77,78 with a grid density of 1 Å -3 was used. For van der Waals and short-range 936 electrostatic interactions, we used a smooth cutoff of 12 Å. CHARMM36m 79 force field parameters 937 were used for the protein, and CHARMM36 force field parameters 80 for the lipids and ions. The 938 page 34 of 43 parameters for picrotoxin were obtained from CGenFF 81,82 . VMD was used for analyzing the MD 939 trajectories. To calculate the pore-radius profiles, we used HOLE 69 . 940
Patch-clamp and single-channel recording 941
Heterologous expression in human embryonic kidney cells. Full-length zebrafish α1 942
GlyR was subcloned into the pcDNA3.1 for expression in the human embryonic kidney 293A cells 943 (HEK293A). Point mutations were using site-directed mutagenesis. HEK293A cells were 944 transiently transfected using the calcium phosphate-DNA precipitation method. The DNA mix 945 consisted of pcDNA3.1 plasmids with inserts coding for the enhanced Green Fluorescence Cells were bathed in an extracellular solution consisting of (in mM): 20 Na D-gluconate, 112.7 959 NaCl, 2 KCl, 2 CaCl2, 1.2 MgCl2, 10 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 960 acid), 40 glucose (all Sigma) and 10 tetraethylammonium chloride (TEACl) (Alfa Aesar); the pH 961 adjusted to 7.4 with NaOH. For the cell-attached recordings, pipettes were filled with extracellular 962 solution containing the required concentration of agonist. To record macroscopic currents, the 963 pipette was filled with a 30 mM chloride intracellular solution, containing (in mM): 101.1 K 964 gluconate, 1 ethylene glycol tetraacetic acid (EGTA), 1 CaCl2, 1 MgCl2, 10 HEPES, 2 MgATP, 965 40 sucrose, 6 KCl (all Sigma) and 20 TEACl, the pH adjusted to 7.4 with NaOH. All solutions were 966 prepared in bi-distilled water or, for cell-attached single channel recordings, in high-performance 967 liquid chromatography grade (HPLC) water (VWR Chemicals), and filtered through a 0.2 µm 968 cellulose nitrate membrane filter (Whatman) before use. Glycine, taurine or GABA-containing 969 solutions were prepared by diluting a 1 M glycine, 1 M taurine or 1 M GABA stock in extracellular 970
solution. 971
Taurine and GABA were purified by 2x recrystallization from aqueous ethanol and 972 subsequently tested for glycine contamination by an HPLC assay: samples were resuspended in 973 10 µl 50% EtOH, reacted for 30 min with 90% EtOH:triethylamine:phenylisothiocyanate (7:2:1), 974 evaporated to dryness at room temperature and redissolved in 100 µl 5% acetonitrile in 0.1 M 975 ammonium acetate. A 150x4.6 mm Hypersil C18 column was used and were detected was 976 measured at 254 nm. The purified taurine and GABA contained no detectable glycine, which in 977 this assay is less than 1 part in 10,000. where the test response rundown was less than 30% during the experiment were accepted for 989 further analysis. No correction for rundown was applied. Different agonist concentrations were 990 applied in random order to obtain concentration-response curves. The peak current amplitudes 991 for each glycine application were measured using Clampfit 10.2 software (Molecular Devices). 992
The concentration-response data for each cell were then fitted with the Hill equation using the 993 CVFIT programme (DCPROGS; https://github.com/DCPROGS/CVFIT) to estimate EC50 (agonist 994 concentration required to elicit 50% maximal response), nH¬ (Hill-slope) and Imax (maximum 995 peak current). 996
Fast agonist application. Macroscopic currents evoked in outside-out patches by fast 997 agonist application pulses were recorded at a pipette holding potential of −100 mV (−111 mV 998 when corrected for a junction potential of 11 mV). The internal solution was the same as the one 999 for whole cell recordings and contained 30 mM chloride. Agonist, dissolved in extracellular 1000 solution, was applied to outside-out patches with a theta tube (Hilgenberg GmbH) cut to a final 1001 diameter of ≈ 150 μm at the tip. Loop B T220 T220 S145 S145 R81 R81 F79 S174 S174 
